Thu-07-05-2020, 15:29 PM
(Thu-07-05-2020, 12:43 PM)Fred Wrote:(Wed-06-05-2020, 20:18 PM)Caroline Wrote:(Wed-06-05-2020, 19:51 PM)Fred Wrote: It's not used in France either.
It is available.
But some group of Management idiots who call themselves experts (PHMR) have advise to not reimburse it. Well then nobody is going to use it.
Again... Kat.... No Knowledge.
All I know is my dermatologist pointed me to this:
Translated by Google:
Quote:
Insufficient clinical interest to justify reimbursement for plaque psoriasis due to its low efficacy and an unfavourable tolerance profile
SKILARENCE has Marketing Authorization in the treatment of moderate to severe plaque psoriasis which requires systemic therapy only in adults.
It has demonstrated low efficacy vis-à-vis the placebo, but there is no data to locate its place in the therapeutic strategy compared to other systemic, biological and non-biological.
Its tolerance profile involves many risks, in particular gastrointestinal disorders, flushing and hematological disorders, some of which are potentially serious such as hepatic, renal, hematological disorders, cancer and risks of serious infections including PML.
The medical service provided by SKILARENCE 30 mg and 120 mg, gastro-resistant tablets, is insufficient in the indication of the Marketing Authorization, in view of the therapies available, to justify treatment by national solidarity.
Yes I know you will pick that to pieces, but as I mentioned it's not available in France and you saying it is I thought I should clarify.
But I'll stop there as this is Jim's thread and I only follow it as I'm interested in his progress.
Indeed Fred.. it is quatsch. Totally does not fit to 35 years of Dutch experience and the risks are far overrated, there is only one risk PML, but that is easy to control.
It all comes down to one thing, lack of knowledge, and not willing to have a open mind.
But it is a valuable text, I will discuss it with Almirall..